As the legal saga between Astellas and two generics firms Lupin and Zydus reached its culmination just a few weeks ago, Lupin’s CEO Vinita Gupta said the company feels certain about the opportunity to relaunch the generic version of Myrbetriq (mirabegron) shortly.
Lupin’s Confidence Over Mirabegron Relaunch Doesn’t Convince Analyst
Uncertainty Leads To Jefferies Maintaining 'Hold' Rating For Lupin
While Lupin is “truly excited with the potential” ahead, the uncertainty around upcoming product launches paints a different financial picture.
